Skip to main content
Premium Trial:

Request an Annual Quote

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

NEW YORK – Natera said on Thursday that coverage of its Signatera minimal residual disease (MRD) test would expand under a new draft local coverage determination (LCD) issued by Centers for Medicare & Medicaid Services' contractor Palmetto GBA through the Molecular Diagnostics (MolDx) program.

The draft LCD expands coverage for circulating tumor DNA tests that detect MRD in patients with a history of cancer to many cancer types and would include coverage of the Signatera test for immunotherapy response monitoring. Natera pointed out that it specifically mentions Signatera and a pan-cancer validation study that the company recently published in Nature Cancer showing that the test, in conjunction with imaging, identified non-responders to the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) with a 100 percent positive predictive value.

Natera said the draft LCD also creates a pathway for coverage of Signatera in additional solid tumor types and indications. The firm said the test has already been validated in multiple cancer types for detecting residual disease up to two years earlier than standard diagnostic tools.

Earlier this month, Natera received coverage for Signatera in advanced colorectal cancer under a final LCD released by Palmetto.

"Medicare's proposed coverage offers enormous benefit to the over 200,000 patients being treated with immune checkpoint inhibitors," said Solomon Moshkevich, Natera's general Manager of oncology, in a statement. "We look forward to working with the oncology community to generate further evidence supporting the clinical value of Signatera in both early-stage and advanced-stage cancers."

Cowen research analysts, in a note to investors, pointed out that Natera's laboratory is under the jurisdiction of Noridian, not Palmetto, and would need to wait for Noridian to issue and finalize an LCD before it can bill CMS. "We believe it should be relatively straightforward for a finalized LCD from Noridian given Signatera is already approved for reimbursements in CRC monitoring," they wrote.

"All in all, we believe this is a massive win for Natera's oncology business," said research analyst for investment bank Piper Sandler, in a note to investors.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.